What question did this study set out to answer?

This case series aims to evaluate the effectiveness of CD38-targeted therapy in severe, refractory immune thrombocytopenia.

Efficacy of CD38 ‐Targeted Therapy in Severe, Multi‐Agent Refractory Immune Thrombocytopenia: A Case Series

View Full Paper

Ask AI

Bookmark

Authors

Case series reveals that CD38-targeted therapy normalizes platelet counts in patients with severe refractory immune thrombocytopenia.

This case series aims to evaluate the effectiveness of CD38-targeted therapy in severe, refractory immune thrombocytopenia.
Describes three patients aged 39, 58, and 85 with life-threatening ITP
Patients failed conventional treatments including corticosteroids, IVIG, and TPO-RAs
Salvage therapy was administered using daratumumab, a CD38-targeted monoclonal antibody
All three patients achieved rapid hematologic recovery
Platelet counts normalized within one week of treatment
The treatment facilitated urgent clinical stabilization for further medical interventions

Patel et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark